Steve D. Barrett, co-chair of the Technology Transactions and Licensing Practice Group, advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements.
Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises. Mr. Barrett serves on the board of directors of The Political Asylum/Immigration Representation (PAIR) Project.
Mr. Barrett has also successfully represented, on a pro bono basis, a number of persons who have fled persecution in other countries and sought political asylum in the United States.
Mr. Barrett served on active duty as a US naval officer from 1989 to 1992. His assignments included division officer tours in USS Hoel (DGG-13) and USS Waddell (DDG-24), and he qualified as a surface warfare officer and was awarded the Navy Achievement Medal.
- Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
- Agios Pharmaceuticals in its Chinese territory collaboration and license agreement for Ivosidenib with CStone Pharmaceuticals (2018)
- Agios Pharmaceuticals in its licensing agreement for metabolic immuno-oncology inhibitors with Aurigene Discovery Technologies Limited (2017)
- Alnylam in its prior collaborations with Medtronic (2007), Takeda (2008), Cubist (2009) and GSK (2011)
- Concert Pharmaceuticals in its prior collaborations with GSK (2009), Avanir Pharmaceuticals (2012) and Jazz Pharmaceuticals (2013)
- Epizyme in its reacquisition of EZH2 inhibitor oncology program rights from Eisai (2015)
- Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
- Merrimack Pharmaceuticals in its >$970 million ex-US license and collaboration agreement with Baxter (2014)
- Nosocomial Vaccine Corporation in its collaboration with Astellas, Affinivax and University of Maryland (2015)
- Summit Therapeutics in its Latin America license and commercialization agreement for its ridinilazole antibiotic for the treatment of Clostridium difficile infection with Eurofarma Laboratórios (2017)
- vTv Therapeutics in its Pacific Rim territory licensing agreement for vTv’s PDE4 inhibitor program with Newsoara Biopharma Co. (2018).
- JD, University of Michigan Law School, 1996
- MBA, University of Michigan, 1996
- SB, Mechanical Engineering, Massachusetts Institute of Technology, 1989
- United States Patent and Trademark Office
Rate : $$$$